Patient Care

Mendel AI Launches Hypercube Platform Powered by AWS

SAN JOSE, Calif. , Sept. 26, 2024 /PRNewswire/ -- Mendel AI, a leader in clinical artificial intelligence (AI), today announced the…

1 year ago

Aesthetic Surgery Center Wins 1st Place in Three Categories in the 2024 Naples Community’s Choice Awards

Aesthetic Surgery Center excels in Naples' 2024 Community's Choice Awards, earning top honors for its expertise in facial and body…

1 year ago

RIVANNA secures patent for groundbreaking ultrasound-guided needle insertion system

CHARLOTTESVILLE, Va., Sept. 25, 2024 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical solutions, announced the acquisition of a groundbreaking…

1 year ago

Piwik PRO Achieves HIPAA Certification, Enabling Data-Driven Marketing and Privacy Compliance for Healthcare Organizations

Ensures compliance for secure and privacy-friendly digital analytics in healthcare WROCŁAW, Poland, Sept. 25, 2024 /PRNewswire/ -- Piwik PRO, a…

1 year ago

The Ultrasound Event 2025: Pioneering the Future of Medical Ultrasound

ORLANDO, Fla., Sept. 25, 2024 /PRNewswire/ -- The American Institute of Ultrasound in Medicine (AIUM) is excited to announce the…

1 year ago

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests

New investment supports DxA's mission to advance the development of scalable and universally accessible diagnostics.Blood tests will be key to…

1 year ago

BMC Helping Customers Improve Lives and Customer Experiences in Healthcare, Financial Services and Energy Sectors

NHS Northumbria patients, Nationwide Building Society members, and EDP customers benefit from the time- and cost-savings BMC delivers using data-driven…

1 year ago

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –…

1 year ago

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2…

1 year ago